Alunbrig (brigatinib)

Brigatinib in crizotinib-naive ROS1 fusion-positive NSCLC @JSMO_official by Dr. Toshiaki Takahashi. Brigatinib demonstrated ORR of 67.9% (90% CI, 50.6-82.1) and met the pre-planned threshold boundary. #JSMO2023 #LCSM (@HHorinouchi)

Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1 Rearranged Non–Small-Cell Lung Cancer https://t.co/htD3gsFbqO (@VivekSubbiah)

WATCH: Focusing on ALK-rearranged NSCLC, expert panelists review data behind alectinib, brigatinib, and lorlatinib. @benlevylungdoc @hopkinskimmel #lcsm #oncology https://t.co/AdwxTPoALh (@OncLive)

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) https://t.co/BFljX1kxWD (@tehfem)

An interesting review showed that #Brigatinib effectively treats patients with #ALK-positive non-small cell #lungcancer. https://t.co/o8ca77lXR9 (@Dr_Ivanoncologo)

Awesome #TumorBoardTuesday by @LeciaSequist discussing #ALK fusion+ #NSCLC Chooing #TKI: 🧠 mets > Lorlatinib vs Brigatinib, NO 🧠 mets > Alectinib vs Btigatinib, type of #mutation_matters #LCAM #LCSM @ALKLungCancer @TumorBoardTues (@FawziAbuRous)

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) https://t.co/PVbPEodjYI (@VivekSubbiah)

Dr. @oncoOuLungCA presents a pooled analysis of ALTA- and J-ALTA showing efficacy of brigatinib after alectinib in #ALK NSCLC. Clear efficacy with RR 31% with mDOR 9.2m and mPFS 5.2m. Can biomarkers further refine therapy? #WCLC22 (@StephenVLiu)

Long term safety and efficacy of brigatinib in crizotinib-refractory #ALK NSCLC in #JTOCRR. In the ALTA trial, mPFS 15.6m with the standard 90mg to 180mg dosing with mOS 40.6m and median intracranial PFS 18.4m with no new safety signals. @JTOonline https://t.co/rHq4wVwzN1 (@StephenVLiu)

Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non–Small-Cell Lung Cancer @notahedge @JCOPO_ASCO https://t.co/h4q4WS8iZj (@VivekSubbiah)

Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1-Rearranged Non–Small-Cell Lung Cancer @JCOPO_ASCO https://t.co/W8fQa0GvET (@VivekSubbiah)

Brigatinib-2nd gen ALKi @TakedaPharma 🎯ALK, IGF-1R, ROS1, FLT-3, EGFR🎯 Use in ALK+NSCLC (1st and 2nd line) See ALTA-1L trial in the app, Brigatinib vs Crizotinib @DrSanjayPopat 💪CNS activityTox: ⬆️QTc & brady,⬆️LFT ILD🫁 Hyperglycemia due to IGF-1R🎯 ⬆️CPK=myalgia ⬆️Lipase (@HemeOncBuddy)

Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1 Rearranged Non–Small-Cell Lung Cancer @notahedge @ASCO_pubs https://t.co/epI4NHAPmB (@VivekSubbiah)

Brigatinib resulted in a 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression compared w/ crizotinib in pts with ALK-positive NSCLC. @DrSanjayPopat @royalmarsdenNHS @myESMO #ESMO21 #lcsm https://t.co/x7GoKcDKTN (@OncLive)

+++ Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non–Small-Cell Lung Cancer @notahedge @ASCO_pubs https://t.co/4uBkDkqJI0 (@VivekSubbiah)

Both poziotinib and alectinib can be combined ; start with lower doses and escalate later. Brigatinib may works for EGFR non20 exon mutations with alk+ mNSCLC (@BapnaAjay)

Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1-Rearranged Non–Small-Cell Lung Cancer @notahedge @ASCO_pubs @ros1cancer #LCSM @Alfdoc2 @StephenVLiu @DrSteveMartin https://t.co/aMRewp9jlg (@VivekSubbiah)

No. If you are going to choose Alectinib or Brigatinib, asymptotic brain mets can be closely watched. As @Dr_R_Kurzrock mentioned Brigatinib may cover EGFR too, so if available may be preferable (maybe!) (@deeptibehl1)

#OncoAlert Updated @ASCO guidelines for treatment of driver+ NSCLC in #JCO @ASCO_pubs. Changes: osimertinib recommended as 1L for #EGFR, alectinib and brigatinib recommended as 1L for #ALK, and targeted options for #RET, #NTRK, #MET endorsed as 1L options https://t.co/SQHxtEv9Oy (@StephenVLiu)

"M/48y Non smoker ECOG 0 Lung Adeno. Stg4 Denovo - Coexisting ALK + (D5F3) + EGFR exon 20 ins. Rx ? Sequence( which 1st) or combine ? Which EGFR Rx - Td-m1 or TKI ? Which ALK TKI ? Any role of Brigatinib ? @LeciaSequist @geoff_oxnard @PatelOncology @StephenVLiu @DrSteveMartin" (@oncologician)

First line Brigatinib for ALK rearranged NSCLC. Where will it feature in your prescribing algorithm? @tnewsomdavis @DrSanjayPopat @DrRiyazShah @tanyaahmad @BTOGORG @AlastairGreyst2 @JoannaStokoe @ShairozMerchan1 @ProfSIAhmed @medicine98 (@OncoloJo)

Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1 Rearranged Non–Small-Cell Lung Cancer @ASCO_pubs https://t.co/xZP1UNYyt7 (@VivekSubbiah)

#OncoAlert Report @JTOonline @IASLC on phase II #ATOMIC study of brigatinib in #ALK NSCLC after next-gen ALK TKI therapy. RR 40%, DOR 5.3m, mPFS 7m. Responses seen with ALK resistance mutations (G1202R, I1171T, L1196M). @rdoebele @HornLeora #LCSM https://t.co/aoWJ1Gu0NP (@StephenVLiu)

ALK rearrangement in #lungcancer has an option of front line use of loratinib says ⁦@CharuAggarwalMD⁩ ⁦@gotoPER⁩ #gotoILCC brigatinib very active agent as well and a sequential approach is preferred ⁦@PennCancer⁩ ⁦@HwakeleeMD⁩ ⁦@drgandara⁩ ⁦ (@donnashort)

Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1-Rearranged Non–Small-Cell #LungCancer @ASCO_pubs @notahedge #LCSM https://t.co/qkxlixkF1y (@VivekSubbiah)

#ASCO20 Response to brigatinib (post-alectinib) noted in the presence of various #ALK resistance mutations including G1202R (1/3), L1196M (3/3), I1171N (1/2), I1171S (1/1). Well tolerated. Most common G3 tox were lipase (no pancreatitis), CK (no myalgias), HTN. #OncoAlert #LCSM (@StephenVLiu)

#OncoAlert At PD on osimertinib, biopsy was sent for NGS and revealed EGFR del19 and T790M and amplification as well as a new ELM4/ALK fusion (with +IHC). Successfully treated with crizotinib + osimertinib then brigatinib + osimertinib. #LCSM (@StephenVLiu)

#MET amplification was seen in 12% of patients post 2nd-gen #ALK TKI and 22% of patients post-lorlatinib. With first line alectinib and brigatinib, MET amplification seems more likely (logical given activity of crizotinib at MET). MET rearrangements also identified! #LCSM (@StephenVLiu)

Brigatinib has been FDA approved for lung cancer treatment in the USA since 2017, one difference is each of those treatments address unique mutations that can develop within the ALK patient. (@ALKLungCancer)